Veeva Systems
Connects life sciences development, quality, data, and commercial workflows in the cloud.
Something off on this page? Send us feedback.
Profile
Provides cloud software, data, and consulting for clinical development, regulatory, safety, quality, and commercial teams in life sciences. Revenue is predominantly subscription-based, and core applications connect regulated content and data on the proprietary Vault platform.
Organizes its life sciences portfolio into Veeva Development Cloud, Veeva Quality Cloud, Veeva Commercial Cloud, and Veeva Data Cloud. The suites cover clinical trials, regulatory submissions, drug safety, manufacturing quality, CRM, commercial content, and healthcare-professional and de-identified patient data; implementation and business consulting supplement the software.
Builds core applications on the proprietary Vault platform, connecting content and data across regulated workflows. Customers range from global biopharma companies to emerging firms, while North America supplies most revenue and Europe is the next-largest region.
Earns most revenue from subscriptions. Life-sciences specialization supports validation and compliance requirements, while Vault CRM is replacing the Salesforce-based legacy CRM. Vault applications rely on Amazon Web Services, and some AI agents use third-party language models. Operates as a Delaware public benefit corporation.
Company facts
Key statistics
Year to date +26.1% · Average volume (30d) 1.9M
Analysts
Ratings
Target range
Latest analyst notes
| Date | Firm | Action | Rating | Prior target | Target |
|---|---|---|---|---|---|
| Aug 27, 2026 | Truist Financial | Target | $217 | $305 | |
| Aug 27, 2026 | Raymond James | Reiterate | Outperform | $225 | $330 |
| Aug 27, 2026 | RBC Capital | Reiterate | Outperform | $250 | $325 |
| Aug 27, 2026 | Evercore ISI | Target | $185 | $250 | |
| Aug 27, 2026 | Stifel Nicolaus | Target | $275 | $300 |
Earnings
EPS
Revenue
History
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Next session |
|---|---|---|---|---|---|---|---|
| Aug 26, 2026Q2 FY27 | $2.23 | $2.35 | +5.4% | $905.4M | $928.0M | +2.5% | +15.20% |
| Jun 3, 2026Q1 FY27 | $2.14 | $2.24 | +4.7% | $857.7M | $882.9M | +2.9% | −0.07% |
| Mar 4, 2026Q4 FY26 | $1.94 | $2.06 | +6.2% | $810.7M | $836.0M | +3.1% | +3.95% |
| Nov 20, 2025Q3 FY26 | $1.95 | $2.04 | +4.6% | $792.8M | $811.2M | +2.3% | −9.77% |
Financial highlights
| 12 quarters | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 | Q2 FY27 | |
|---|---|---|---|---|---|---|---|
| Revenue | $759.0M | $789.1M | $811.2M | $836.0M | $882.9M | $928.0M | |
| Gross profit | $585.2M | $593.8M | $611.8M | $622.5M | $659.7M | $696.0M | |
| Operating income | $233.7M | $195.9M | $240.9M | $245.9M | $273.1M | $275.0M | |
| Net income | $228.2M | $200.3M | $236.2M | $244.2M | $260.9M | $273.4M | |
| Diluted EPS | $1.37 | $1.19 | $1.40 | $1.45 | $1.57 | $1.66 | |
| Gross margin | 77.1% | 75.3% | 75.4% | 74.5% | 74.7% | 75.0% | |
| Operating margin | 30.8% | 24.8% | 29.7% | 29.4% | 30.9% | 29.6% |
Fiscal years (4-quarter sums)FY22 $1.85B · FY23 $2.16B · FY24 $2.36B · FY25 $2.75B · FY26 $3.20B
Revenue by product · Q2 FY27
Revenue by geography · Q2 FY27
Balance sheet, Jul 31, 2026Cash & short-term investments $7.24B · Total debt $151.7M · Total assets $9.06B · Shareholders' equity $7.43B
Dividends
No dividends on record.
Ownership
A 13F quarter can total more than the shares outstanding — sub-advisers file the same block twice, and a filer's own share count can be a quarter stale. No split is drawn from it.
Shares outstanding 162.44M · Float 148.91M · 91.7% free float
Top shareholders13F · 13D/G · Form 4
| Holder | Shares | % outstanding | Form | Filed |
|---|---|---|---|---|
| BlackRock, Inc. | 12.86M | 7.92% | 13F | Aug 7, 2026 |
| Vanguard Capital Management | 11.21M | 6.89% | 13G | Jul 31, 2026 |
| Vanguard Portfolio Management LLC | 7.41M | 4.56% | 13F | Aug 13, 2026 |
| State Street Corp | 6.71M | 4.13% | 13F | Aug 7, 2026 |
| Principal Financial Group Inc | 4.98M | 3.07% | 13F | Aug 4, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Aug 13, 2026 | Thomas D. Schwenger | officer: Pres. & Chief Customer Officer | −36,000 | $250.23 |
| Jul 16, 2026 | Thomas D. Schwenger | officer: Pres. & Chief Customer Officer | −5,000 | $200.00 |
| Apr 30, 2026 | Priscilla Hung | director | −750 | $155.64 |
| Apr 10, 2026 | Priscilla Hung | director | −750 | $153.50 |
| Mar 5, 2026 | Thomas D. Schwenger | officer: Pres. & Chief Customer Officer | −1,000 | $200.00 |
Peers
- IQVIA
Pharma data incumbent competing in CRM, HCP data, and commercial analytics.
- Salesforce
Horizontal CRM giant turned direct pharma rival with Agentforce Life Sciences.
- Oracle
Enterprise tech giant competing in eClinical, pharmacovigilance, and R&D data.
CompareAfter-hours close
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Veeva Systems | $276.99 | +0.12% | $44.95B | 45.5 | 29.2 | 13.0 | +17.6% |
| IQVIA | $261.75 | +0.03% | $43.08B | 32.5 | 19.2 | 2.5 | +8.7% |
| Salesforce | $256.48 | +0.16% | $209.66B | 23.4 | 17.6 | 4.8 | +10.8% |
| Oracle | $150.95 | +0.17% | $434.14B | 25.9 | 18.7 | 6.4 | +20.6% |
| Median | 25.9 | 18.7 | 4.8 | +10.8% |